Hier finden Sie grundlegende Angaben zu laufenden klinischen Studien des Comprehensice Cancer Centers Mainfranken (CCC MF)
Filter aktiv
Seite 1 - Studien 1 bis 2 von insgesamt 2
  • A phase I/IIa clinical trial to assess feasibility, safety and antitumor activity of autologous SLAMF7 CAR-T cells in multiple myeloma

    Indikationen
    Molekulare Marker
  • Elotuzumab (E) in Combination with Carfilzomib, Lenalidomide and Dexamethasone (E-KRd) versus KRd prior to and following Autologous Stem Cell Transplant in Newly Diagnosed Multiple Myeloma and Subsequent Maintenance with Elotuzumab and Lenalidomide verus Single-Agent Lenalidomide
    A phase III study by DSMM (Deutsche Studiengruppe Multiples Myelom)
    Indikationen
    Molekulare Marker